Carprofen and meloxicam are clinically equivalent for chronic pain management in dogs with osteoarthritis — no evidence supports superiority of either drug. Both produce significant improvement in ground reaction forces, lameness, weight-bearing, pain on palpation, and owner-assessed mobility, but direct head-to-head data are limited to two trials, and the overall strength of evidence is rated weak.Veterinary Evid…
The most informative direct comparison found that meloxicam-treated dogs had ground reaction forces return to normal baseline values, with owners reporting gait improvement, while carprofen-treated dogs also showed significant improvement in the same parameters.Veterinary Evid… However, the ground reaction force data were not conclusive across all parameters, no validated owner metrology instrument was used, and one of the two comparative trials provided no statistical analysis — only a descriptive suggestion that meloxicam performed better.Veterinary Evid… Neither finding is sufficient to recommend one drug over the other.
Meloxicam is dosed at 0.2 mg/kg PO on day 1, then 0.1 mg/kg PO q24h from day 2 onward, a regimen validated across two placebo-controlled field studies totaling 277 dogs, with statistically significant improvement in all veterinarian- and owner-assessed parameters at 14 days.FDA DailyMed An… Carprofen's efficacy for osteoarthritis is well-established as an active comparator — 89.1% of carprofen-treated dogs demonstrated overall improvement at approximately six weeks in a 134-day trial, and the benefit continued to increase through day 44 and was sustained through day 134.Veterinary Reco…
Long-term NSAID use in dogs does not show increased organ-based toxicity with extended treatment and demonstrates a positive trend toward increased efficacy over time.AAHA Clinical G… Gastrointestinal toxicity is the most commonly recognized adverse effect class for NSAIDs as a group.BMC Veterinary… At 5× the recommended meloxicam dose, acute renal failure developed by day 4, fecal occult blood was detected, and gastrointestinal mucosal lesions ranging from hemorrhage to erosion were observed — confirming that toxicity is dose-dependent rather than an expected finding at therapeutic doses.FDA DailyMed An…
In practice, the choice between carprofen and meloxicam for canine osteoarthritis is appropriately driven by individual patient factors, owner compliance with once-daily dosing, and clinician familiarity, not by a demonstrated efficacy difference between the two drugs.Veterinary Evid…+1
| Drug | Dose | Efficacy in OA | Key Caveat |
|---|---|---|---|
| Meloxicam | 0.2 mg/kg PO day 1, then 0.1 mg/kg PO q24h | Significant improvement all parameters at 14 days; GRF returned to baseline in one comparative trialFDA DailyMed An…+1 | GRF advantage over carprofen not conclusive across all parametersVeterinary Evid… |
| Carprofen | Per label q24h or q12h | 89.1% overall improvement at ~6 weeks; benefit sustained through 134 daysVeterinary Reco… | No placebo-controlled head-to-head data with adequate sample size vs. meloxicamVeterinary Evid… |
Would you like a comparison of grapiprant versus these two NSAIDs for dogs where gastrointestinal or renal concerns make traditional NSAID use higher risk?